Water Exchange and CO2 Insufflation with Abdominal Compression Device to Reduce Manual Assistance
Launched by EVERGREEN GENERAL HOSPITAL, TAIWAN · Jul 4, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new method for performing colonoscopies, which are procedures used to examine the inside of the colon for issues like polyps or signs of colorectal cancer. The researchers want to find out if using water exchange along with a special device that helps compress the abdomen can reduce the need for manual pressure on the stomach during the procedure. This could make the experience more comfortable for patients and potentially improve the ease of the procedure.
To participate in this trial, individuals must be between the ages of 45 and 80 and have an average risk for colorectal cancer. This includes those scheduled for a colonoscopy for screening or follow-up after a positive stool test. However, people with certain medical conditions, such as hereditary colon cancer syndromes or severe abdominal issues, cannot participate. If eligible, participants can expect to undergo a standard colonoscopy while the researchers compare this new method against the traditional approach. It’s important to note that this trial is currently recruiting participants, and anyone interested should speak to their doctor for more information.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged 45-80 years having an average risk for colorectal cancer who plan to undergo sedated outpatient colonoscopy for screening, surveillance, and those who have received a positive fecal immunochemical test result
- Exclusion Criteria:
- • Patients with hereditary colorectal cancer syndrome, including familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer (Lynch syndrome)
- • Patients with serrated polyposis syndrome
- • Patients with known or suspected inflammatory bowel disease
- • Patients with a history of colorectal cancer or other intra-abdominal malignancy
- • Patients with a history of colorectal resection
- • Patients with a history of abdominal aortic aneurysm, cirrhosis, ascites, or other severe comorbid illnesses
- • Patients with recent wounds or skin rash on the anterior abdominal wall and back
- • Patients with known ventral hernia
- • Patients with unsedated procedure
- • Patients with planned bidirectional endoscopy
- • Patients with body mass index \>35 kg/m2
- • Patients with waist circumference \<55 cm or \>105 cm
- • Patients with known or suspected gastroparesis
- • Patients with planned therapeutic procedures (e.g., hemostasis, removal of a large polyp)
- • Patients with mental retardation
- • Pregnant women or those planning pregnancy
- • Patients unwilling to participate in the study
About Evergreen General Hospital, Taiwan
Evergreen General Hospital, located in Taiwan, is a leading healthcare institution dedicated to advancing medical research and clinical innovation. With a strong commitment to patient care and safety, the hospital actively sponsors clinical trials aimed at evaluating new treatments and interventions across various medical disciplines. Leveraging a multidisciplinary team of experienced clinicians and researchers, Evergreen General Hospital fosters a collaborative environment that promotes groundbreaking studies and enhances the understanding of healthcare practices. The institution adheres to the highest ethical standards and regulatory guidelines, ensuring rigorous trial design and execution to contribute valuable insights to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taoyuan, , Taiwan
Kaohsiung, , Taiwan
Patients applied
Trial Officials
Chi-Liang Cheng
Principal Investigator
Evergreen General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported